The U.S. cardiac ablation market is rapidly growing, driven by rising cardiac arrhythmia cases and innovative technologies like pulsed field ablation. Leading companies such as Medtronic, Johnson & Johnson, Abbott, and Boston Scientific are advancing treatments through R&D, clinical trials, and FDA-approved devices.
The U.S. cardiac ablation market size is calculated at US$ 1.92 billion in 2024, grew to US$ 2.19 billion in 2025, and is projected to reach around US$ 7.2 billion by 2034. The market is expanding at a CAGR of 14.19% between 2025 and 2034.
Growth in cardiac arrhythmia: Due to the growing incidence of cardiac arrhythmias in the U.S., there is a rise in the demand for the use of cardiac ablation solutions. Therefore, to tackle them, the companies are innovating various devices. Thus, to accelerate the development, companies are investing and launching new funding rounds.
For instance,
The development of new techniques such as pulsed field ablation and refining the existing technologies to enhance their safety, efficiency, and effectiveness, and reduce their collateral tissue damage is the focus of the R&D of cardiac ablation.
Key Players: Medtronic, Johnson & Johnson, Abbott Laboratories, Boston Scientific.
The clinical trials and regulatory approval of the cardiac ablation focus on the evaluation of their safety and efficacy for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT).
Key Players: Johnson & Johnson, Medtronic, Abbott Laboratories, Boston Scientific.
The preoperative education, monitoring, and personalized postoperative care plans to promote successful recovery are included in the patient support and services of the cardiac ablation.
Key Players: Johnson & Johnson, Boston Scientific, Medtronic, Abbott Laboratories.
In April 2025, after announcing the positive clinical outcomes of the Affera™ family of technologies for atrial fibrillation (AFib), Director of Cardiac Arrhythmia Services for the Mount Sinai Health System in New York City, Vivek Reddy, stated that, various treatment option for different cardiac arrhythmias can be provided with this Affera technology which consists of intuitive, advanced mapping system and catheters. Moreover, circumferential lesions without using catheter rotation were provided by Sphere-360, which contributed to the positive results, safety, and performance profile without any serious adverse effects. Thus, its approval will be a valuable addition to the Affera system of Medtronic.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
